Remdesivir against coronavirus, hope or hype?

On 22 May 2020, preliminary data from a placebo-controlled randomised trial of remdesivir in 1063 patients hospitalized with Covid-19 with lower respiratory tract involvement was published in the New England Journal of Medicine (NEJM). There was a lot of enthusiasm and governments in many countries immediately declared that they would make remdesivir available. I shall…

Read more

The review on antidepressant withdrawal that Cochrane won’t publish

Peter Gøtzsche and Anders Sørensen on trying to get a review of methods for safe antidepressant withdrawal published in Cochrane: “They sent us on a mission that was impossible to accomplish” to “protect the psychiatric guild.” About half of the patients on depression pills, or over 50 million people worldwide, will experience withdrawal symptoms when…

Read more

The mantra of evidence-based medicine stifles important psychiatric research

“We live in the era of evidenced-based practice. If an approach is not funded, then it will never acquire the kind of data that would allow it to be considered evidence-based. This creates a closed loop: only research that is hypothesized to be of value is funded; understudied approaches that might be of value are…

Read more

Defamation and editorial misconduct in a Wiley journal

It is a serious offence to fabricate and publish defamatory lies about a colleague in a medical journal and even worse when the journal and the publisher cover this up. I discuss here my futile attempts to get the truth out and to rebut a mendacious essay published by Oxford professor Trisha Greenhalgh and three…

Read more

More drug deaths: Merck and PTC Therapeutics want clinical study reports to be secret

Yet again, two US drug companies are trying to reintroduce secrecy. Merck and PTC Therapeutics have appealed an initial ruling that clinical study reports should not be considered confidential. On 11 September, Advocate General of the European Court of Justice, Gerard Hogan, found that disclosure of the documents would harm the companies’ commercial interests. The…

Read more

Book review: Death of a whistleblower and Cochrane’s moral collapse

… it was because Professor Gøtzsche was prepared to call out the lowering of scientific standards in Cochrane that the hierarchy felt compelled to plot his demise …  one of the worst show trials ever … in a manner that mirrors how the drug industry operates … the death of Cochrane rather than the whistleblower.…

Read more

Science and censorship — my story

By Maryanne Demasi, Ph.D. August 19, 2019. Science is facing a crisis of democracy. Now more than ever, vitriolic attacks are being leveled at people who debate opposing scientific views. Asking questions that challenge the establishment may be unsettling, but silencing debate and proclaiming that the “science is settled” is not the solution. Belgian physician…

Read more

Meeting in Erice, Sicily, 7-9 October 2019 about reducing drug harms

Sponsored by the Uppsala Monitoring Centre and co-arranged by the Centre for Evidence-Based Medicine in Oxford, 34 invited people participated in a three-day workshop, “Improving the detection, analysis and reporting of harms in medicines: exploring, enhancing and empowering.” It has been shown in several independent studies that prescription drugs are the third leading cause of…

Read more

Go to Top